Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

elephone replay will be available through November 6, 2008.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents, ANA598, a non- nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ANA773 for the treatment of cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to the expected timing and planned development activities for ANA598 and ANA773, including the trial design, occurrence, timing, and pace of future clinical trials, the timing for obtaining viral load data and expectations regarding such data, as well as the anticipated future clinical benefits of ANA598 and ANA773. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward- looking statements. For example, the results of preclinical studies and early clinical trials may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. In addition, Anadys' results may be affected by competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to enter into collaborations around its product candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical t
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Quantum Center at Skolkovo) and Mario Ziman (Masaryk ... of Physics in Bratislava, Slovakia) have found a ... through an amplifier and, conversely, when transmitting a ... an article published in the journal Physical ... particles are considered to be the basis of ...
(Date:7/23/2014)... Last year, Formedix celebrated its partnership ... of data management solutions for clinical trials. The company ... electronic data capture (EDC) and clinical data management. Formedix, ... tools added TrialMaster to its Transform for EDC product ... for TrialMaster, is being released this week, in response ...
(Date:7/23/2014)... MOINES, Iowa (PRWEB) July 23, 2014 ... join the business as vice president of Agricultural Biotechnology ... Mendel Biotechnology where he served most recently as president, ... extensive biotechnology and business leadership in the seed and ... Pioneer,” said Paul E. Schickler , president of ...
(Date:7/23/2014)...  Sofinnova Ventures, a Menlo Park ... Sofinnova Venture Partners IX, L.P. at the hard cap ... fund target of $425 million. Sofinnova focuses ... with recent funds, SVP IX will provide capital primarily ... with select investments in earlier stage opportunities. Investments will ...
Breaking Biology Technology:Scientists find way to maintain quantum entanglement in amplified signals 2Scientists find way to maintain quantum entanglement in amplified signals 3Scientists find way to maintain quantum entanglement in amplified signals 4Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 3DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3Sofinnova Raises $500 Million Biotech Venture Fund 2
... The single-atom thick material graphene maintains its high ... step to advancing the material from a laboratory phenomenon ... devices, researchers report in the April 9 issue of ... engineers and theoretical physicists from the University of Texas ...
... Mechanical Engineering at Stevens Institute of Technology was named ... (YIP) award by the Office of Naval Research (ONR). ... exceptional promise for creative study. "We are proud ... said ONR,s Director of Research Dr. Michael Kassner. "Through ...
... ... Regulatory Submissions , ... Rockville, MD (Vocus) April 8, 2010 -- Bringing its popular interactive workshop to Europe ... eCTD Submissions in Brussels, 5–7 May. This introductory workshop guides participants on how to ...
Cached Biology Technology:With support, graphene still a superior thermal conductor 2Dr. Chang-Hwan Choi honored with prestigious Young Investigator Award 2Dr. Chang-Hwan Choi honored with prestigious Young Investigator Award 3RAPS to Host eCTD Submissions Workshop in Brussels 2RAPS to Host eCTD Submissions Workshop in Brussels 3
(Date:7/23/2014)... the world have no access to clean drinking water. ... people die from water-related diseases every year. ETH student ... contribution to solving this problem. Working with researchers from ... Functional Materials Laboratory, the 23-year-old spent a year researching ... makes our DrinkPure filter unique is that you can ...
(Date:7/23/2014)... personalized cancer medicine, (the WIN consortium), recently announced that ... University will be one of its six new ... in the Tri-State Area. The goal of WIN is ... the patient by forging collaborations between partners in academia, ... WIN consortium means Jefferson cancer patients will have access ...
(Date:7/23/2014)... potential for clinical use of induced pluripotent stem ... previously been hindered by the risk of dysregulated ... ability to use etoposide treatment to halt teratoma ... disease, specifically acute myocardial infarction, is demonstrated in ... , a peer-reviewed journal from Mary Ann Liebert, ...
Breaking Biology News(10 mins):ETH student develops filter for clean water around the world 2New partnership brings more personalized cancer treatment to Philadelphia 2
... research professor and professor emeritus at The University of ... the American Academy of Arts & Sciences (AAAS), along ... Earl Jones, U.S. Secretary of Defense Robert Gates and ... scientist who translates his discoveries into technology that helps ...
... New York Sea Grant (NYSG) announces the release of ... Populations in South Shore Bays of Long Island, NY, ... of five research projects funded through NYSG,s Hard Clam ... NOAA National Marine Fisheries Service, South Shore Estuary Reserve, ...
... In Maine, government scientists have figured out how to measure ... and the sun - all the while saving money, energy, ... this energy-efficient ingenuity was the need to help the National ... spring snowmelt. The problem was this: While the USGS ...
Cached Biology News:University of Texas at Austin engineer elected to American Academy of Arts and Sciences 2University of Texas at Austin engineer elected to American Academy of Arts and Sciences 3Sea Grant report synthesizes recent research on New York's clams 2Measuring snow with a bucket, a windmill, and the sun? 2
... Expansion Kit - Neurosphere is a system designed ... expansion as neurospheres in a serum free environment. ... Media Supplement, which has been optimized for neural ... . (1996) Genes & Development 10 :3129). ...
Request Info...
... RQ1 RNase-Free DNase is a ... single-stranded or double-stranded DNA to produce ... for use in applications where maintaining ... RQ1 DNase is qualified for use ...
... Polymerase I catalyzes the template-directed polymerization of ... direction. DNA Polymerase I possesses a 3?5 ... the error rate during DNA replication, and ... enables the enzyme to replace nucleotides in ...
Biology Products: